High expression of CCAR2 correlates with low overall survival or a poor prognosis for patients with breast cancer [44, 45], clear cell renal cell carcinoma [46], colon cancer [8, 47], diffuse large B cell lymphoma [48], esophageal squamous cell carcinoma [13], gastric cancer [9, 49, 50], hepatocellular carcinoma [51], laryngeal and hypopharyngeal carcinoma [52], osteosarcoma [6], ovarian carcinoma [53], and soft tissue sarcoma [54]. This evidence concerns the gene CCAR2 and diffuse large B-cell lymphoma.